| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2011: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2010: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2009: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Research Abstract |
Neutrophilic inflammation and Th17-type immune responses are characteristics of airway inflammation in severe asthma. Dopamine D1-like receptor(D1-like-R) antagonist suppresses Th17 differentiation. In this study, we clarified that D1-like-R antagonist significantly suppressed ovalbumin(OVA)-induced neutrophilic airway inflammation. It also inhibited the production of IL-17 and infiltration of Th17 cells in the lung. Further, it suppressed the production of IL-23 by lung CD11c+antigen-presenting cells. These findings suggest the possibility that antagonizing D1-like-R serves as a promising new strategy for controlling neutrophil-dominant severe asthma.
|
